Exploring the potential of Gonolobus condurango as a histone deacetylase inhibitor in triple-negative breast cancer cell lines: in vitro study
Abstract Background Triple-negative breast cancer (TNBC) is a subtype associated with poor prognosis, low survival rates, and high expression of histone deacetylases (HDAC). Treatment with HDAC inhibitors (HDACi) induces the acetylation of histones and thereby the expression of tumor suppressive miR...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | BMC Complementary Medicine and Therapies |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12906-025-04896-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849309706869276672 |
|---|---|
| author | Beate Vajen Vera Schäffer Marlies Eilers Brigitte Schlegelberger Britta Skawran |
| author_facet | Beate Vajen Vera Schäffer Marlies Eilers Brigitte Schlegelberger Britta Skawran |
| author_sort | Beate Vajen |
| collection | DOAJ |
| description | Abstract Background Triple-negative breast cancer (TNBC) is a subtype associated with poor prognosis, low survival rates, and high expression of histone deacetylases (HDAC). Treatment with HDAC inhibitors (HDACi) induces the acetylation of histones and thereby the expression of tumor suppressive miRNAs that regulate proliferation, apoptosis, migration, and differentiation. Gonolobus condurango (GC) has been reported to exhibit HDAC inhibitory effects, and this study aims to investigate whether GC acts as a HDACi in TNBC cell lines. Methods Expression and acetylation analyses were performed on the TNBC cell lines HCC38, HCC1395, and HCC1937. Cells were treated with HDAC inhibitors Trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), or Romidepsin as well as with GC Urtincture and different dilutions of GC. Tumor-relevant functional effects were analyzed using WST-1-based proliferation and Caspase-3/7 based apoptosis assays. Induction of expression of tumor-suppressive miRNAs hsa-miRNA-192-5p (miR-192) and hsa-miR-194-2 (miR-194) was analyzed by qRT-PCR. Results Meta-analyses of gene expression showed a significant reduction in HDAC1 and HDAC2 expression in triple-negative breast cancer samples. The TNBC cell lines (HCC38, HCC1395, and HCC1937) used for in vitro assays also exhibited reduced expression of HDAC1, HDAC2, HDAC3, and HDAC4 and low acetylation levels. Treatment with the HDAC inhibitors TSA, SAHA, or Romidepsin induced acetylation, while GC did not. TSA and GC Urtincture induced apoptosis in HCC38, whereas GC dilutions had no effect. Treatment with TSA forced the expression of tumor suppressive miRNAs miR-192 and miR-194, but neither GC Urtincture nor any GC dilution induced the expression of these miRNAs. Conclusion Several classes of HDAC inhibitors have been shown to be potent and specific anticancer agents. In this study, Gonolobus condurango showed no HDAC inhibitory effect in the TNBC cell lines. Identifying new HDAC inhibitors is important, but they must be well characterized before being used as therapeutic agents in humans. |
| format | Article |
| id | doaj-art-2f157b1dfe9845449c30d1b994570044 |
| institution | Kabale University |
| issn | 2662-7671 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Complementary Medicine and Therapies |
| spelling | doaj-art-2f157b1dfe9845449c30d1b9945700442025-08-20T03:53:58ZengBMCBMC Complementary Medicine and Therapies2662-76712025-05-0125111110.1186/s12906-025-04896-wExploring the potential of Gonolobus condurango as a histone deacetylase inhibitor in triple-negative breast cancer cell lines: in vitro studyBeate Vajen0Vera Schäffer1Marlies Eilers2Brigitte Schlegelberger3Britta Skawran4Department of Human Genetics, Hannover Medical SchoolDepartment of Human Genetics, Hannover Medical SchoolDepartment of Human Genetics, Hannover Medical SchoolDepartment of Human Genetics, Hannover Medical SchoolDepartment of Human Genetics, Hannover Medical SchoolAbstract Background Triple-negative breast cancer (TNBC) is a subtype associated with poor prognosis, low survival rates, and high expression of histone deacetylases (HDAC). Treatment with HDAC inhibitors (HDACi) induces the acetylation of histones and thereby the expression of tumor suppressive miRNAs that regulate proliferation, apoptosis, migration, and differentiation. Gonolobus condurango (GC) has been reported to exhibit HDAC inhibitory effects, and this study aims to investigate whether GC acts as a HDACi in TNBC cell lines. Methods Expression and acetylation analyses were performed on the TNBC cell lines HCC38, HCC1395, and HCC1937. Cells were treated with HDAC inhibitors Trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), or Romidepsin as well as with GC Urtincture and different dilutions of GC. Tumor-relevant functional effects were analyzed using WST-1-based proliferation and Caspase-3/7 based apoptosis assays. Induction of expression of tumor-suppressive miRNAs hsa-miRNA-192-5p (miR-192) and hsa-miR-194-2 (miR-194) was analyzed by qRT-PCR. Results Meta-analyses of gene expression showed a significant reduction in HDAC1 and HDAC2 expression in triple-negative breast cancer samples. The TNBC cell lines (HCC38, HCC1395, and HCC1937) used for in vitro assays also exhibited reduced expression of HDAC1, HDAC2, HDAC3, and HDAC4 and low acetylation levels. Treatment with the HDAC inhibitors TSA, SAHA, or Romidepsin induced acetylation, while GC did not. TSA and GC Urtincture induced apoptosis in HCC38, whereas GC dilutions had no effect. Treatment with TSA forced the expression of tumor suppressive miRNAs miR-192 and miR-194, but neither GC Urtincture nor any GC dilution induced the expression of these miRNAs. Conclusion Several classes of HDAC inhibitors have been shown to be potent and specific anticancer agents. In this study, Gonolobus condurango showed no HDAC inhibitory effect in the TNBC cell lines. Identifying new HDAC inhibitors is important, but they must be well characterized before being used as therapeutic agents in humans.https://doi.org/10.1186/s12906-025-04896-wGonolobus CondurangoTriple-negative breast cancerHistone deacetylase inhibitor |
| spellingShingle | Beate Vajen Vera Schäffer Marlies Eilers Brigitte Schlegelberger Britta Skawran Exploring the potential of Gonolobus condurango as a histone deacetylase inhibitor in triple-negative breast cancer cell lines: in vitro study BMC Complementary Medicine and Therapies Gonolobus Condurango Triple-negative breast cancer Histone deacetylase inhibitor |
| title | Exploring the potential of Gonolobus condurango as a histone deacetylase inhibitor in triple-negative breast cancer cell lines: in vitro study |
| title_full | Exploring the potential of Gonolobus condurango as a histone deacetylase inhibitor in triple-negative breast cancer cell lines: in vitro study |
| title_fullStr | Exploring the potential of Gonolobus condurango as a histone deacetylase inhibitor in triple-negative breast cancer cell lines: in vitro study |
| title_full_unstemmed | Exploring the potential of Gonolobus condurango as a histone deacetylase inhibitor in triple-negative breast cancer cell lines: in vitro study |
| title_short | Exploring the potential of Gonolobus condurango as a histone deacetylase inhibitor in triple-negative breast cancer cell lines: in vitro study |
| title_sort | exploring the potential of gonolobus condurango as a histone deacetylase inhibitor in triple negative breast cancer cell lines in vitro study |
| topic | Gonolobus Condurango Triple-negative breast cancer Histone deacetylase inhibitor |
| url | https://doi.org/10.1186/s12906-025-04896-w |
| work_keys_str_mv | AT beatevajen exploringthepotentialofgonolobuscondurangoasahistonedeacetylaseinhibitorintriplenegativebreastcancercelllinesinvitrostudy AT veraschaffer exploringthepotentialofgonolobuscondurangoasahistonedeacetylaseinhibitorintriplenegativebreastcancercelllinesinvitrostudy AT marlieseilers exploringthepotentialofgonolobuscondurangoasahistonedeacetylaseinhibitorintriplenegativebreastcancercelllinesinvitrostudy AT brigitteschlegelberger exploringthepotentialofgonolobuscondurangoasahistonedeacetylaseinhibitorintriplenegativebreastcancercelllinesinvitrostudy AT brittaskawran exploringthepotentialofgonolobuscondurangoasahistonedeacetylaseinhibitorintriplenegativebreastcancercelllinesinvitrostudy |